PARSABIV (Etelcalcetide Hydrochloride Injection) – Mechanism of Action and Dosage

0
650

Below is a detailed description of the mechanism of action and dosage of PARSABIV (Etelcalcetide Hydrochloride Injection):

Mechanism of Action

PARSABIV is a synthetic calcimimetic peptide drug. Its active ingredient, etelcalcetide, specifically binds to and activates the calcium-sensing receptors (CaSR) on the surface of parathyroid cells. By mimicking the physiological effects of increased serum calcium, it suppresses parathyroid hormone (PTH) secretion. This mechanism simultaneously reduces serum calcium and phosphate levels, improving mineral metabolism disorders in patients with secondary hyperparathyroidism (SHPT).

Dosage and Administration

1. Formulation and Strength
Injection formulations:

  • 0.5 ml: 2.5 mg (single-dose vial)

  • 1 ml: 5 mg (pre-filled syringe)

  • 2 ml: 10 mg (amber glass light-protected vial)

Characteristics: Clear, colorless solution, pH 7.4, citrate buffer; store at 2–8 °C protected from light.

2. Dosing Regimen

  • Initial dose: 5 mg intravenous bolus, three times weekly (administered at the end of dialysis), injection duration ≥1 minute.

  • Dose adjustment: Adjust in 2.5 mg or 5 mg increments based on PTH and corrected serum calcium, up to a maximum dose of 15 mg/week.

    • Adjustment interval: ≥4 weeks

    • Target PTH range: 150–300 pg/mL (as recommended by KDIGO guidelines).

  • Special populations: For patients weighing <50 kg, a starting dose of 2.5 mg is recommended.

3. Administration Considerations

  • Monitoring requirements:

    • Corrected serum calcium (weekly), PTH (monthly), phosphate (every 2 weeks).

    • Closely monitor ECG changes after first administration or dose adjustment.

  • Administration method:

    • Must be injected into the arterial line of the dialysis circuit; do not mix with calcium-containing solutions.

  • Missed dose: If a dialysis session is missed, no supplementation is required; continue with the usual dose at the next dialysis session.

Adverse Reactions

Common adverse reactions include hypocalcemia (requiring immediate calcium supplementation), muscle cramps, diarrhea, and nausea. In terms of cardiovascular benefits, a ≥30% reduction in FGF23 has been associated with an 18% lower risk of major cardiovascular events.


Note: This information was compiled and edited by Hong Kong DengYue Medicine. It provides updates on the latest globally marketed drugs. For specific prescribing guidance, please consult your physician.

Pesquisar
Categorias
Leia Mais
Outro
How Quality Fittings and Water Filtration Improve Industrial Efficiency in UAE
Industrial operations in the UAE, especially in oil, gas, and water sectors, rely heavily on the...
Por Marine Supply 2025-09-24 10:17:32 0 463
Outro
GoLang App Development Company
In recent years, GoLang (or Go) has become one of the most popular programming languages for...
Por Linda Echol 2025-08-26 05:59:14 0 1K
Outro
Healthcare Business Intelligence Market Size, Analysis, Scope, Demand, Opportunities, Statistics
"Executive Summary: Healthcare Business Intelligence Market Size and Share by...
Por Shweta Kadam 2025-09-25 06:13:51 0 311
Outro
Best Women’s Swimwear for Summer Beach Fashion in 2025
Summer is all about sun, sea, and stunning swimwear. As 2025 brings fresh beach fashion trends,...
Por LAGE NCE 2025-09-25 07:55:50 0 436
Outro
Why Hiring a Website Development Company in USA Boosts Business Growth
In today’s fast-moving digital world, having a website is essential. Every business needs a...
Por Elena Jonathan 2025-08-29 22:42:32 0 1K